Every material Form 8-K Seres Therapeutics, Inc. has filed with the SEC since August 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Seres reported a third-quarter 2026 net loss of $16.3 million, compared with net income of $8.2 million a year earlier, when a $25 million VOWST sale installment was recognized as a gain. The company said its cash and cash equivalents of $17.5 million at September 30, 2026, plus a $12.5 million payment from Nestlé received in October, fund operations only through the first quarter of 2027, excluding any new partnership or capital proceeds.
Q3 2026 net loss of $16.3 million (-$1.63 per share) vs. net income of $8.2 million ($0.94 per share) in Q3 2025
Grant revenue rose to $593 thousand from $351 thousand; R&D expenses fell to $5.6 million from $12.6 million, and G&A to $5.4 million from $9.5 million
A $5.7 million non-cash impairment charge related to the early termination of the 200 Sidney Street lease
Cash runway expected through Q1 2027; company plans to submit an irEC study design to the FDA in Q1 2027 and says funding is required
Seres Therapeutics said Chief Financial Officer Marella Thorell resigned from her executive vice president and CFO roles on October 22, 2026, effective November 15, 2026. The company said she is expected to provide advisory services after that date to support an orderly transition, on terms still to be agreed.
Marella Thorell resigned as EVP and Chief Financial Officer on October 22, 2026
Resignation takes effect November 15, 2026
Thorell is expected to provide advisory services to support an orderly transition, terms not yet agreed
Seres reported second quarter 2026 net income of $4.6 million, compared with a net loss of $19.9 million a year earlier, driven by a $25 million gain from the Nestlé milestone termination payment. The company had $15.6 million in cash at June 30, 2026, and expects to fund operations through the first quarter of 2027, excluding any future partnership or financing proceeds.
Q2 2026 net income $4.6 million vs. net loss $19.9 million in Q2 2025; difference mainly the $25 million VOWST gain
Research and development expenses $9.1 million (vs. $12.9 million) and G&A $7.1 million (vs. $10.3 million)
$5.8 million impairment charge tied to early termination of part of the 101 Cambridgepark Drive lease
Cash of $15.6 million at June 30, 2026; runway through Q1 2027 assumes the $12.5 million Nestlé payment due October 1, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Seres Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →